Jongwe, Tsungai Ivai Chapman, Ros Douglass, Nicola Chetty, Shivan Chege, Gerald Williamson, Anna-Lise Determination of the optimal dosage of MVA-Gag<sup>M</sup> to boost a BCG-Gag<sup>M</sup> prime. <p>(<b>A)</b> Mice were primed on day 0 with 2 x 10<sup>7</sup> cfu BCG-Gag<sup>M</sup> (Group 1–3) or BCG<sup>E</sup> (Group 4–6) and boosted on day 70 with 10<sup>2</sup> (Group 1 and 4), 10<sup>4</sup> (Group 2 and 5), or 10<sup>6</sup> (Group 3 and 6) pfu MVA-Gag<sup>M</sup>. (<b>B</b>) Cumulative IFN-γ ELISPOT CD8<sup>+</sup> and CD4<sup>+</sup> responses of vaccinated mice to HIV-1 Gag peptides. The ELISPOT assay was carried out using three Gag-specific peptides for stimulation of pooled splenocytes that were isolated 12 days post the MVA-Gag<sup>M</sup> boost. Bars represent the magnitude of net responses to individual peptides, expressed as sfu/10<sup>6</sup> splenocytes after subtracting the background. (<b>C</b>) and (<b>D</b>) Total frequency of T cells producing IFN-γ, IL-2, and/or TNF-α, after subtracting the background, in response to HIV-1 Gag peptide stimulation following a rBCG prime and an MVA-Gag<sup>M</sup> boost at different doses. Cells were positive for cytokine production if the proportion was ≥0.05% after subtracting the background. These results are from a single experiment using pooled splenocytes.</p> MVA Elicits Persistent Effector T Cell Responses;Subtype C Mosaic Gag;MVA-Gag M;HIV -1C mosaic Gag;subtype C;Th 1 bias;Mycobacterium bovis BCG Δ panCD auxotroph;Gag-specific IFN -γ ELISPOT responses;BCG-Gag M;HIV -1C viruses;11.5 weeks post vaccination;effector memory phenotype;T cell epitopes;BALB;BCG-Gag M vaccine;T cell Gag-specific IFN -γ ELISPOT response;TNF;IL 2016-07-18
    https://plos.figshare.com/articles/figure/Determination_of_the_optimal_dosage_of_MVA-Gag_sup_M_sup_to_boost_a_BCG-Gag_sup_M_sup_prime_/3895614
10.1371/journal.pone.0159141.g004